澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

TELIX PHARMACEUTICALS LTD

16.160

0.000

成交量：99.58萬

成交額：1,604.14萬

市值：54.74億

市盈率：121.25

高：16.250

開：16.180

低：15.910

收：16.160

52周最高：18.950

52周最低：8.260

股本：3.39億

流通股本：2.75億

量比：0.34

換手率：0.36%

股息：- -

股息率：- -

每股收益(TTM):0.133

每股收益(LYR):-0.029

淨資產收益率：7.36%

總資產收益率：2.71%

市淨率：8.03

市盈率(LYR):-548.13

資料載入中...

總覽公司新聞資訊公告

Telix Pharmaceuticals預計2026財年營收及其他收入將突破10億美元

Telix Pharmaceuticals與摩根士丹利及威廉·布萊爾簽署股票分銷協議

Telix Pharmaceuticals持續推進：美國生物製品許可申請重新遞交進入關鍵階段

澳大利亞Telix製藥公司因季度營收表現強勁而股價上漲

Telix Pharmaceuticals Ltd 預計2026財年營收及其他收入將突破10億美元

傑富瑞認為，在ProstACT獲FDA批准後，澳大利亞Telix公司有望如期進軍美國市場

Telix宣佈合作探索PSMA-PET成像在前列腺癌新興療法中的應用

TELIX PHARMACEUTICALS LTD可轉換債券初始轉換價格定為每股13.85美元

Telix製藥有限公司初始轉換價將高於當前股價

TELIX PHARMACEUTICALS LTD子公司擬發行5.5億美元2031年到期可轉換票據

BUZZ-泰利克斯與再生元達成抗癌協議，股價上漲

再生元製藥公司向TELIX支付4000萬美元首付款

BUZZ-澳大利亞泰利克斯製藥公司因 4,000 萬美元的再生元交易而上漲；花旗銀行認為交易範圍 "更廣"。

異動解讀 | Telix製藥盤中大漲7.58%，因達成重大許可協議獲鉅額預付款及里程碑款項

Telix製藥有限公司將獲4000萬美元預付款及高達21億美元里程碑款項加特許權使用費

BUZZ-晨星預計澳大利亞泰利克斯製藥公司利潤率將擴張，維持收入預期

Telix Pharmaceuticals Ltd 向美國FDA重新提交腦癌成像候選藥物TLX101-PX（Pixclara™）新藥申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/TLX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":16.16,"timestamp":1787638320000,"preClose":16.16,"halted":0,"volume":995818,"delay":0,"changeRate":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13325733476948268,"marketStatus":"未開盤","change":0,"latestTime":"08-25 16:12:00 AEST","open":16.18,"high":16.25,"low":15.91,"amount":16041439,"amplitude":0.02104,"askPrice":16.19,"askSize":1999,"bidPrice":16.1,"bidSize":2571,"shortable":3,"etf":0,"ttmEps":0.13325733476948268,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":16.16,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.34397193008615995,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":16.16,"auctionPrice":16.17,"auctionVolume":162822,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203502}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029482,"volumeRatio":0.34397193008615995,"shares":338721355,"dividePrice":0,"high":16.25,"amplitude":0.02104,"preClose":16.16,"low":15.91,"week52Low":8.26,"pbRate":"8.03","psRate":"4.40","week52High":18.95,"institutionHeld":0,"latestPrice":16.16,"committee":0.125164,"eps":0.13327725738302296,"divideRate":0,"volume":995818,"delay":0,"ttmEps":0.13327725738302296,"open":16.18,"prevYearClose":11.2,"prevWeekClose":15.62,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.76,"twentyDayClose":14.47,"sixtyDayClose":13.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1117100091","title":"Telix Pharmaceuticals預計2026財年營收及其他收入將突破10億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117100091","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117100091?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 09:55","pubTimestamp":1787190931,"startTime":"0","endTime":"0","summary":"8月20日（路透社）——Telix Pharmaceuticals Limited宣布，其2026财年的营收及其他收入预计将超过10亿美元。该公司上半年集团营收达到4.77亿美元，税后利润为3800万美元。\n此外，Telix已与摩根士丹利和William Blair & Co签署了股权分销协议，旨在建立“按市价”融资机制。这一举措预计将为公司提供更多资本运作的灵活性。\n更多公司详情，请参考TLX.AX的相关报道。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136595917","title":"Telix Pharmaceuticals與摩根士丹利及威廉·布萊爾簽署股票分銷協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1136595917","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136595917?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 06:47","pubTimestamp":1787179647,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals已与摩根士丹利及威廉·布莱尔公司正式签署了一项股票分销协议。此举标志着该公司在资本市场上的又一重要战略布局，旨在进一步优化其融资渠道并增强财务灵活性。根据该协议，Telix Pharmaceuticals将通过这两家知名金融机构进行股票的分销活动。目前，Telix Pharmaceuticals尚未披露该协议的具体财务条款或预期的发行规模，但市场普遍预计，这一合作将为其带来可观的资本补充，助力其在全球范围内的创新药物研发和商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197836734","title":"Telix Pharmaceuticals持續推進：美國生物製品許可申請重新遞交進入關鍵階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1197836734","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197836734?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 06:45","pubTimestamp":1787179508,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals在重新向美国递交Tlx250-Px（即Zircaix）生物制品许可申请的道路上，正不断取得实质性进展。\n公司表示，朝着近期重新提交这一关键申请的目标，已迈出坚实步伐。这一动向标志着Telix在推动其核心产品进入美国市场的进程中，又向前推进了一步。\n从目前披露的信息来看，Telix Pharmaceuticals显然正以积极的姿态，为Tlx250-Px及Zircaix在美上市铺平道路。市场对此持续关注，而公司的推进节奏也透露出对这款产品前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226824","title":"澳大利亞Telix製藥公司因季度營收表現強勁而股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226824","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226824?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 13:23","pubTimestamp":1784611422,"startTime":"0","endTime":"0","summary":"BUZZ-澳大利亚Telix制药公司因季度营收表现强劲而股价上涨更新：花旗、杰富瑞研报7月21日-** Telix Pharmaceuticals（TLX.AX）股价一度上涨4.2%至15.73澳元，创下自7月6日以来的最大盘中百分比涨幅** 这家大型生物制药公司 (link) 公布2026年第二季度营收为2.47亿美元，较去年同期增长21%** 预计2026财年营收及其他收入将超过10亿美元**","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4T43N0A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU2125154778.USD","LU1201861249.SGD","LU1074936037.SGD","LU0052756011.USD","FTXO","LU0170899867.USD","LU0314106906.USD","LU2417539215.USD","IYF","BK4585","LU1668664300.SGD","LU1506573853.SGD","LU1791807156.HKD","BK4504","BK4207","LU0106831901.USD","LU1244550494.USD","LU0128525689.USD","BK7067","LU0130102774.USD","BK4559","LU0310800965.SGD","BK4588","IE00BSNM7G36.USD","LU0162691827.USD","LU2125154935.USD","LU0203345920.USD","LU0320765646.SGD","LU2456880835.USD","LU2462157665.USD","LU0648001328.SGD","LU2236285917.USD","TFNS","LU0980610538.SGD","LU1244550577.SGD","LU0098860793.USD","LU2360032135.SGD","LU0130517989.USD","LU0203347892.USD","LU0477156953.USD","LU0072461881.USD","BK4534","LU1244550221.USD","LU1267930227.SGD","BK4566","LU1366192091.USD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131203391","title":"Telix Pharmaceuticals Ltd 預計2026財年營收及其他收入將突破10億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131203391","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131203391?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 06:28","pubTimestamp":1784586493,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd 日前发布预测，公司2026财年的总营收及其他收入有望超过10亿美元大关。这一乐观预期凸显了公司在放射性药物领域强劲的增长势头和市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648680520","title":"傑富瑞認為，在ProstACT獲FDA批准後，澳大利亞Telix公司有望如期進軍美國市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2648680520","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648680520?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 03:26","pubTimestamp":1783020371,"startTime":"0","endTime":"0","summary":"BUZZ-杰富瑞认为，在ProstACT获FDA批准后，澳大利亚Telix公司有望如期进军美国市场7月2日-** 杰富瑞表示，Telix公司针对前列腺癌开展的TLX.AXProstACT临床试验正按计划推进至美国阶段，预计将于2027年公布中期影像学无进展生存期分析数据** 这家医疗科技公司周四表示， (link) 已获美国药品监管机构批准将其全球ProstACT试验的第二部分扩展至美国，并认定第","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL4T4341I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137496886","title":"Telix宣佈合作探索PSMA-PET成像在前列腺癌新興療法中的應用","url":"https://stock-news.laohu8.com/highlight/detail?id=1137496886","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137496886?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 18:31","pubTimestamp":1778841068,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd近日宣布，已与多家机构达成合作，旨在探索PSMA-PET成像技术在前列腺癌新兴治疗策略中的潜在应用。这项合作将聚焦于利用先进的分子影像技术，优化前列腺癌的诊断与治疗路径，为患者提供更精准的个性化医疗方案。通过整合影像学与临床治疗数据，研究团队期望能够推动前列腺癌治疗领域的创新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067","EDAP","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198320680","title":"TELIX PHARMACEUTICALS LTD可轉換債券初始轉換價格定為每股13.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198320680","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198320680?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 06:15","pubTimestamp":1776204911,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD（ASX: TLX）近日公布了其即将发行的可转换债券的初始转换价格。根据公告，该转换价格设定为每股13.85美元。这一价格将成为债券持有人未来将其持有的债券转换为公司普通股的基础定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109569829","title":"Telix製藥有限公司初始轉換價將高於當前股價","url":"https://stock-news.laohu8.com/highlight/detail?id=1109569829","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109569829?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 14:56","pubTimestamp":1776149807,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd（ASX: TLX）最新披露的融资条款显示，其可转换债券的初始转换价格将设定在高于公司当前股价的水平。\n这一溢价定价机制反映了发行方对Telix长期价值增长的信心，同时也为债券持有人提供了潜在的股本增值机会。市场分析人士指出，此类条款常见于成长型生物技术企业的融资结构，既能降低即时股权稀释影响，又能吸引注重长期价值的投资者。\n随着Telix在前列癌诊断放射性药物领域的商业化进程加速，此次融资将为全球市场拓展提供关键资金支持。投资者将密切关注6月30日季度报告中的现金流状况及产品上市进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110649910","title":"TELIX PHARMACEUTICALS LTD子公司擬發行5.5億美元2031年到期可轉換票據","url":"https://stock-news.laohu8.com/highlight/detail?id=1110649910","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110649910?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 14:56","pubTimestamp":1776149791,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD（ASX: TLX）宣布，其全资子公司将启动发行规模达5.5亿美元、2031年到期的可转换票据。此次发行为公司战略融资计划的重要组成部分，旨在优化资本结构并支持长期业务发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627347334","title":"BUZZ-泰利克斯與再生元達成抗癌協議，股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2627347334","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627347334?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 18:49","pubTimestamp":1776077358,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4T40W0PF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU1974910355.USD","BK4588","LU0114720955.EUR","LU2362541273.HKD","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","BK4139","LU1917777945.USD","LU0823434740.USD","LU2106854487.HKD","LU0889565916.HKD","LU2362541513.USD","LU2362540622.SGD","LU0320765992.SGD","BK7067","BK4585","LU2237438978.USD","TLX.AU","LU0823416689.USD","LU0882574055.USD","LU2023250504.SGD","LU0053666078.USD","LU0823434583.USD","LU0289739699.SGD","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182410565","title":"再生元製藥公司向TELIX支付4000萬美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1182410565","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182410565?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 18:33","pubTimestamp":1776076393,"startTime":"0","endTime":"0","summary":"根据最新合作协议，TELIX PHARMACEUTICALS LTD将获得来自再生元制药公司的一笔总额为4000万美元的预付款项。此次交易标志着两家生物技术企业在创新药物研发领域的重要合作进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","BK4585","BK4139","LU1917777945.USD","LU0058720904.USD","BK7067","LU2468319806.SGD","BK4588","LU0320765992.SGD","LU2106854487.HKD","LU2237438978.USD","LU1974910355.USD","LU0823434740.USD","LU0823416689.USD","LU0823434583.USD","LU0882574055.USD","LU0889565916.HKD","LU2362541513.USD","LU0289739699.SGD","LU0109394709.USD","LU0114720955.EUR","LU0053666078.USD","LU2089984988.USD","LU2362541273.HKD","TLX.AU","LU2023250504.SGD","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627860483","title":"BUZZ-澳大利亞泰利克斯製藥公司因 4,000 萬美元的再生元交易而上漲；花旗銀行認為交易範圍 \"更廣\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2627860483","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627860483?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 10:39","pubTimestamp":1776047956,"startTime":"0","endTime":"0","summary":"(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4T40W04L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0058720904.USD","LU2089984988.USD","LU2106854487.HKD","LU2362540622.SGD","BK4585","LU1917777945.USD","REGN","TLX.AU","LU0109394709.USD","LU2362541273.HKD","LU0320765992.SGD","LU0053666078.USD","BK7067","LU2023250504.SGD","LU2468319806.SGD","LU0114720955.EUR","LU1974910355.USD","BK4588","LU0889565916.HKD","LU2237438978.USD","BK4139","LU0823434583.USD","LU0882574055.USD","LU0823434740.USD","LU0823416689.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169836260","title":"異動解讀 | Telix製藥盤中大漲7.58%，因達成重大許可協議獲鉅額預付款及里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=1169836260","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169836260?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 08:04","pubTimestamp":1776038653,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) 今日盘中大涨7.58%，引起了市场的广泛关注。消息面上，公司宣布达成一项重大许可协议，根据协议条款，Telix将获得4000万美元的预付款。此外，若未来达成特定的研发、监管和商业化里程碑，公司还有资格获得总额高达21亿美元的款项。协议还包括基于未来产品销售的特许权使用费安排。此项交易凸显了Telix在放射性药物领域领先技术的价值及其产品的巨大市场潜力，极大地增强了投资者对公司未来现金流和长期增长前景的信心，从而推动了股价的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173287378","title":"Telix製藥有限公司將獲4000萬美元預付款及高達21億美元里程碑款項加特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1173287378","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173287378?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 06:29","pubTimestamp":1776032954,"startTime":"0","endTime":"0","summary":"Telix制药有限公司（ASX: TLX）宣布达成一项重大许可协议，根据协议条款，公司将获得4000万美元的预付款。此外，若未来达成特定的研发、监管和商业化里程碑，Telix还有资格获得总额高达21亿美元的款项。协议还包括基于未来产品销售的特许权使用费安排。此项交易凸显了Telix在放射性药物领域领先技术的价值及其产品的巨大市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","REGN","TLX.AU","BK4585","LU0109394709.USD","LU2237438978.USD","LU2362540622.SGD","LU1974910355.USD","LU2362541273.HKD","LU0289739699.SGD","LU0053666078.USD","LU0320765992.SGD","LU2023250504.SGD","LU2089984988.USD","LU0823416689.USD","LU0058720904.USD","LU0882574055.USD","BK4588","LU1917777945.USD","LU0889565916.HKD","LU2106854487.HKD","LU2362541513.USD","BK4139","LU0823434583.USD","LU0114720955.EUR","BK7067","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625965636","title":"BUZZ-晨星預計澳大利亞泰利克斯製藥公司利潤率將擴張，維持收入預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2625965636","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625965636?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 03:59","pubTimestamp":1775591947,"startTime":"0","endTime":"0","summary":"4月7日 - ** 晨星预计泰利克斯制药公司TLX.AX的息税前利润率到中期将扩张29%。** TLX周二公布  季度集团收入为2.3亿美元，重申2026年收入预期为9.5亿-9.7亿美元。** 晨星公司表示：\"泰利克斯有望实现我们对其 2026 年 9.6 亿美元的收入预期，我们维持这一预期不变。\"** 投资者研究公司称，核心前列腺癌成像的增长将继续支撑泰利克斯的业绩表现** 晨星公司预计，随着 2026 年 TLX 的管线产品 Pixclara的成功上市，该公司的发展势头将持续下去。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4S40Q1FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2065731478.USD","TLX.AU","BK4157","LU1878469433.USD","TNLX","MORN","BK7067","BK4598"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116737586","title":"Telix Pharmaceuticals Ltd 向美國FDA重新提交腦癌成像候選藥物TLX101-PX（Pixclara™）新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1116737586","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116737586?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609615,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Telix Pharmaceuticals Ltd已正式向美国食品药品监督管理局重新递交了其脑癌成像候选药物TLX101-PX的新药申请。此次提交标志着该创新型诊断工具在获批道路上迈出关键一步。TLX101-PX是一种基于放射性示踪剂的成像剂，专门设计用于精准检测脑肿瘤病灶。公司此次重新提交的申请材料包含最新临床数据，旨在进一步验证Pixclara在复杂脑癌病例中的诊断效能。若获批准，该产品将成为脑癌诊疗领域的重要突破，为全球神经肿瘤患者提供更精准的诊疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}